[1]庞贺莉.不同剂量氟维司群治疗雌激素受体阳性晚期乳腺癌的疗效[J].医学信息,2020,33(02):136-137.[doi:10.3969/j.issn.1006-1959.2020.02.039]
　PANG He-li.Effect of Different Doses of Fulvestrant in Patients with Estrogen Receptor Positive Advanced Breast Cancer[J].Medical Information,2020,33(02):136-137.[doi:10.3969/j.issn.1006-1959.2020.02.039]
点击复制

不同剂量氟维司群治疗雌激素受体阳性晚期乳腺癌的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年02期
页码:
136-137
栏目:
药物与临床
出版日期:
2020-01-15

文章信息/Info

Title:
Effect of Different Doses of Fulvestrant in Patients with Estrogen Receptor Positive Advanced Breast Cancer
文章编号:
1006-1959（2020）02-0136-02
作者:
庞贺莉
（辽宁省瓦房店市中心医院肿瘤内一科，辽宁 瓦房店 116300）
Author(s):
PANG He-li
(Department of Oncology,Subject One,Wafangdian Central Hospital,Wafangdian116300,Liaoning,China)
关键词:
氟维司群; 乳腺癌晚期; 雌激素受体阳性
Keywords:
Fulvestrant; Advanced breast cancer; Estrogen receptor positive
分类号:
R373.9
DOI:
10.3969/j.issn.1006-1959.2020.02.039
文献标志码:
A
摘要:
目的 研究氟维司群的用药剂量对雌激素受体阳性乳腺癌晚期患者疗效的影响。方法 选取2018年3月~2019年3月本院收治并诊断为雌激素受体阳性乳腺癌晚期患者60例，随机分为高剂量组（n=25）和低剂量组（n=35）。高剂量组给予500 mg氟维司群治疗，低剂量组给予250 mg氟维司群治疗。比较两组临床治疗效果，不良反应及无进展生存时间（PFS）。结果 高剂量组的ORR与CBR均高于低剂量组[12.00% vs 11.43%，52.00% vs 45.72%]，但差异无统计学意义（P＞0.05）。高剂量组的PFS为5.5个月，低剂量组的PFS为4.9个月，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 高剂量（500 mg）氟维司群对处于晚期的雌激素受体阳性乳腺癌患者的生存有一定的改善作用，未增加不良反应的发生。
Abstract:
Objective To study the effect of the dose of Fulvestrant on the efficacy of advanced estrogen receptor-positive breast cancer patients. Methods 60 patients with advanced estrogen receptor-positive breast cancer admitted to our hospital from March 2018 to March 2019 were randomly divided into high-dose group (n=25) and low-dose group (n=35). The high-dose group was given 500 mg fulvestrant and the low-dose group was given 250 mg fulvestrant. The clinical effects, adverse reactions, and progression-free survival (PFS) were compared between the two groups.Results The ORR and CBR in the high-dose group were higher than those in the low-dose group[12.00% vs 11.43%，52.00% vs 45.72%], but the difference was not statistically significant(P>0.05). The PFS in the high-dose group was 5.5 months, and the PFS in the low-dose group was 4.9 months,the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion High-dose (500 mg) fulvestrant can improve the survival of patients with advanced estrogen receptor-positive breast cancer without increasing the incidence of adverse reactions.

参考文献/References:

[1]黄雪香.绝经后激素受体阳性晚期乳腺癌的内分泌治疗[J].国际肿瘤学杂志,2016,43(7):529-531. [2]唐荣彬,王若雨,吕金燕,等.不同剂量氟维司群治疗雌激素受体阳性晚期乳腺癌患者的疗效[J].实用药物与临床,2019,22(2):21-23. [3]邓颖斐,薛聪,安欣,等.依维莫司和氟维司群在内分泌耐药晚期乳腺癌中的疗效对比[J].实用医学杂志,2018,34(10):9-12. [4]高潺潺.氟维司群单药/联合在晚期乳腺癌治疗中疗效和安全性的Meta分析[D].东南大学,2017. [5]Moscetti L,Fabbri MA,Natoli C,etal.Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world:the Ful500 prospective observational trial[J].Oncotarget,2017,8(33):54528-54536.

相似文献/References:

[1]王丹宁,赵金波.氟维司群治疗绝经后激素受体阳性晚期乳腺癌的 临床研究进展[J].医学信息,2018,31(13):4.[doi:10.3969/j.issn.1006-1959.2018.13.002]
　WANG Dan-ning,ZHAO Jin-bo.Progress in the Clinical Study of Fulvestrant in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer[J].Medical Information,2018,31(02):4.[doi:10.3969/j.issn.1006-1959.2018.13.002]

更新日期/Last Update: 2020-01-15